FEELM
19.5.2022 10:43:11 CEST | Business Wire | Press release
FEELM, the flagship atomization tech brand belonging to SMOORE, today released its “Race to Zero” plan and roadmap to carbon neutrality. The plan brings forward FEELM’s ambitions to achieve net-zero carbon emissions by 2050 in its direct production activities and indirect purchased energy (scope 1&2). Meanwhile, FEELM makes a commitment that renewable energies will account for 30% of its total energy consumption by 2030.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220519005482/en/
As one of China’s first atomization tech brands to make a carbon neutrality commitment, FEELM pledges to reach net zero in full supply chain and full product lifespan by developing sustainable products, improving energy efficiency with automated production, supporting the supply chain in decarbonization, and increasing renewable energies and eco-friendly materials.
FEELM, being the world ‘s largest closed vape system solution provider, plays a significant role in the global vaping supply chain. On the one hand, it provides millions of global consumers with premium product experience by virtue of partnership with vaping brands around the world; on the other hand, FEELM has been leading a sustainable revolution in the supply chain.
Leading on Sustainability by introducing FUTURE series solutions
FEELM has been leading on sustainability and green product innovations, which is the industry’s driving force towards carbon neutrality. Committed to providing global customers with zero carbon technologies, FEELM has introduced FUTURE series solutions, which feature recyclability, disassemblability, biodegradability and minimalist design.
Since 2019, FEELM has already pioneered a number of green vaping solutions. For example, it won iF Design Award 2020 for disposable paper e-cigarette, which is made up of spiral composite paper tube, improving the degradability rate to approximately 76% of the total volume, compared with the plastic used in traditional vaping products.
Moreover, FEELM is ready to unveil another eco-friendly non-nicotine disposable e-cigarette at Vaper Expo UK 2022 in late May . This product was awarded Red Dot Awards for Product Design 2022. Its external structure is composed of recyclable and reusable aluminum foil. It looks like a paper foil pouch and itself serves as a packaging bag, hence the reduction of packaging materials.
Supporting the Global Supply Chain in Decarbonization
In addition to developing sustainable products, FEELM has also partnered with suppliers to develop and encourage utilizing biodegradable materials while optimizing the water, electricity and gas consumption management. FEELM is also working with global customers to promote the recycling and reusing, so as to explore a feasible path towards carbon neutrality for the product lifespan and the supply chain.
As a manufacturer with environmental awareness, FEELM has supported vaping brands around the world in reducing carbon footprint and empowered our customers to achieve carbon neutrality in 2050, by eliminating unnecessary plastic packaging. For example, FEELM removed single-use plastics from packaging of one of its major customers. Having removed silicone caps from e-liquid pods, it replaced all plastic tray packaging with a pulp alternate. By 2020, FEELM had already helped this customer save over 100 tons of disposable plastics, which are equivalent to 4 million plastic bottles.
To date, China has accounted for close to 90% of global production of vaping products. As the world ‘s largest closed vape system solution provider, FEELM is devoted to facilitating carbon neutrality of the whole supply chain. It has been exploring innovative, customized carbon reduction solutions along with partners, covering a full circle from raw material supply, product design, production, consumption to recycling and reusing.
FEELM has established a series of automated production lines to optimize energy efficiency. According to its in-house greenhouse gas control and water management procedures, FEELM’s greenhouse gas emissions and water consumption have decreased by 16% and 9.4% year-on-year in 2021 respectively. For example, one of FEELM’s automatic factory has saved 2.298 million kilowatts of electricity, which is equivalent to a reduction of 601 tons of carbon emissions in 2021.
Complying with International Standards, and Making Carbon Management More Transparent
Aiming for the goal that 30% of total energy consumption will come from renewable source by 2030, FEELM is also benchmarked against the standards of international organizations. In 2022, FEELM has introduced Carbon Disclosure Project (CDP) standards to its operation and production. Moving forward, FEELM plans to set up science-based emission reduction targets by submitting to Science Based Targets initiative (SBTi).
The Science Based Targets initiative (SBTi) is a collaboration established in 2015 between CDP, the United Nations Global Compact, World Resources Institute (WRI) and the World Wide Fund for Nature (WWF). By May 11, 2022, there are 2,466 companies from more than 70 countries and regions have joined the initiative, including 152 Chinese companies and one fifth of Forbes 500 companies.
“As a pioneer in going global in Chinese vaping industry, FEELM has been leveraging its full supply chain advantages and fundamental R&D in reducing carbon footprints. As China has pledged to be carbon neutral by 2060, FEELM is ready to fulfill its carbon neutral commitment to Chinese vaping industry, so as to explore a lower-carbon, greener and more sustainable development path with cutting-edge technologies,” said Frank Han, Senior Vice President of SMOORE and President of FEELM.
Moving forward, FEELM will continue to reduce the carbon footprints of vaping products by promoting the R&D and application of innovative green technologies and eco-friendly materials. In collaboration with suppliers and clients, FEELM is also committed to exploring and developing the recycling and reusing mechanism of vape pod cartridges, thereby playing a more significant role in the decarbonization of the industry.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220519005482/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES Publishes FY2025 EU Taxonomy Restatement31.7.2026 07:30:00 CEST | Press release
SES today published a restatement of its FY2025 EU Taxonomy (Article 8) disclosure. The restatement updates the FY2025 EU Taxonomy disclosure included in the 2025 Annual Report and supersedes the previously published disclosure. The FY2025 EU Taxonomy Restatement is available on the SES website: https://www.ses.com/sites/ses_v2/files/investor-files/2026-07/EU_Taxonomy_Report_Restatement_2025.pdf Follow us on: X | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where they are. With integrated multi-orbit satellites and our global terrestrial network, we deliver resilient, seamless connectivity and the highest quality video content to those shaping what’s next. Following our Intelsat acquisition, we now offer more than 100 years of combined global industry l
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
